Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.38 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20364373 | 0.90 | TAS2R8 (0.41) | F10HTR2CHTR2BRIPK1SCD | |
| SCHEMBL20162130 | 0.88 | CYP3A4 (0.43) | HTR2CHTR2BRIPK1SCD | |
| SCHEMBL20162118 | 0.85 | TAS2R8 (0.36) | F10RIPK1CDK5CDK5R1TAS2R8 | |
| SCHEMBL20169955 | 0.85 | PTGER1 (0.49) | HTR2CHTR2BTAS2R8PTGER1 | |
| SCHEMBL20169996 | 0.82 | HTR2C (0.46) | HTR2CHTR2BRIPK1PHF8CDK5 | |
| SCHEMBL19303966 | 0.79 | GRM5 (0.50) | RIPK1PHF8SCDCDK5CDK5R1 | |
| SCHEMBL20364357 | 0.78 | MAP3K5 (0.41) | RIPK1SCDCDK5CDK5R1 | |
| SCHEMBL19303980 | 0.78 | RAB9A (0.52) | PHF8CDK5CDK5R1 | |
| SCHEMBL20162132 | 0.76 | TAS2R8 (0.49) | TAS2R8PTGER1 | |
| SCHEMBL19303965 | 0.76 | GRM4 (0.53) | PHF8SCDCDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| EP-3323809-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | NR0B1, NR2E1, NR0B2 | F10 986/4885HTR2C 1471/4885HTR2B 2579/4885 |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | NR0B1, NR2E1, NR0B2 | F10 986/4885HTR2C 1471/4885HTR2B 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.